Effects of Dopamine D2 Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-11C]DOPA

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Ito, Hiroshi ^a   Takano, Harumasa ^a   Arakawa, Ryosuke ^a   Takahashi, Hidehiko ^a   Kodaka, Fumitoshi ^a   Takahata, Keisuke ^a   Nogami, Tsuyoshi ^a   Suzuki, Masayuki ^a   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BETA LEVODOPA C 11; DEHYDROARIPIPRAZOLE; DOPAMINE; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CARBON; DIAGNOSTIC AGENT; LEVODOPA; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; RACLOPRIDE;

ADULT; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MECHANISM; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC POTENTIAL; PUTAMEN; RECEPTOR OCCUPANCY; REST; SCHIZOPHRENIA; SINGLE DRUG DOSE; BINDING COMPETITION; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG POTENTIATION; METABOLISM; NEUROIMAGING; SCINTISCANNING; TISSUE DISTRIBUTION;

ADULT; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; CARBON RADIOISOTOPES; CAUDATE NUCLEUS; DOPAMINE; HUMANS; LEVODOPA; MALE; NEUROIMAGING; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; QUINOLONES; RACLOPRIDE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84866975247     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046488     Document Type: Article

References (43)

1. Farde L, Wiesel FA, Halldin C, Sedvall G, (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry 45: 71-76.
2. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, et al. (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99: 463-472.
3. Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B, (1993) 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology 110: 265-272.
4. Sparshatt A, Taylor D, Patel MX, Kapur S, (2010) A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry 71: 1447-1456.
5. Lieberman JA, (2004) Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18: 251-267.
6. Gjedde A, Reith J, Dyve S, Leger G, Guttman M, et al. (1991) Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci U S A 88: 2721-2725.
7. Cumming P, Ase A, Laliberte C, Kuwabara H, Gjedde A, (1997) In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain. J Cereb Blood Flow Metab 17: 1254-1260.
8. Torstenson R, Hartvig P, Langstrom B, Bastami S, Antoni G, et al. (1998) Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone. Neuropharmacology 37: 989-995.
9. Danielsen EH, Smith D, Hermansen F, Gjedde A, Cumming P, (2001) Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo. Synapse 41: 172-175.
10. Carlsson A, Lindqvist M, (1963) Effect Of Chlorpromazine Or Haloperidol On Formation Of 3methoxytyramine And Normetanephrine In Mouse Brain. Acta Pharmacol Toxicol (Copenh) 20: 140-144.
11. Der-Ghazarian T, Charntikov S, Varela FA, Crawford CA, McDougall SA, (2010) Effects of repeated and acute aripiprazole or haloperidol treatment on dopamine synthesis in the dorsal striatum of young rats: comparison to adult rats. J Neural Transm 117: 573-583.
12. Vernaleken I, Kumakura Y, Cumming P, Buchholz HG, Siessmeier T, et al. (2006) Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage 30: 1332-1339.
13. Grunder G, Vernaleken I, Muller MJ, Davids E, Heydari N, et al. (2003) Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28: 787-794.
14. Ito H, Takano H, Takahashi H, Arakawa R, Miyoshi M, et al. (2009) Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[β-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission? J Neurosci 29: 13730-13734.
15. Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, et al. (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27: 248-259.
16. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, et al. (2007) Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164: 1411-1417.
17. Grunder G, Fellows C, Janouschek H, Veselinovic T, Boy C, et al. (2008) Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 165: 988-995.
18. Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, et al. (2008) Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 33: 3111-3125.
19. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, et al. (1995) 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinon e (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274: 329-336.
20. Vernaleken I, Kumakura Y, Buchholz HG, Siessmeier T, Hilgers RD, et al. (2008) Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: a positron emission tomography study in healthy subjects. Neuroimage 40: 1222-1231.
21. Grace AA, (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41: 1-24.
22. Oshibuchi H, Inada K, Sugawara H, Ishigooka J, (2009) Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats. Eur J Pharmacol 615: 83-90.
23. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, et al. (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60: 681-690.
24. Takahata K, Ito H, Takano H, Arakawa R, Fujiwara H, et al. (2012) Striatal and extrastriatal dopamine D2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [11C]raclopride and [11C]FLB457. Psychopharmacology (Berl) in press.
25. Pehek EA, McFarlane HG, Maguschak K, Price B, Pluto CP, (2001) M100,907, a selective 5-HT2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res 888: 51-59.
26. Balsara JJ, Jadhav JH, Chandorkar AG, (1979) Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology (Berl) 62: 67-69.
27. Korsgaard S, Gerlach J, Christensson E, (1985) Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 118: 245-252.
28. Hicks PB, (1990) The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 47: 1609-1615.
29. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, et al. (1997) Performance evaluation of a whole-body PET scanner using the NEMA protocol. J Nucl Med 38: 1614-1623.
30. Watson CC, Newport D, Casey ME (1996) A single scatter simulation technique for scatter correction in 3D PET. In: Grangeat P, Amans JL, editors. Three-dimensional image reconstruction in radiology and nuclear medicine. Dordrecht, The Netherlands: Kluwer Academic Publishers. pp. 255-268.
31. Sugaya Y, Sasaki Y, Goshima Y, Kitahama K, Kusakabe T, et al. (2001) Autoradiographic studies using L-[14C]DOPA and L-DOPA reveal regional Na+-dependent uptake of the neurotransmitter candidate L-DOPA in the CNS. Neuroscience 104: 1-14.
32. Ito H, Ota M, Ikoma Y, Seki C, Yasuno F, et al. (2006) Quantitative analysis of dopamine synthesis in human brain using positron emission tomography with L-[β-11C]DOPA. Nucl Med Commun 27: 723-731.
33. Molden E, Lunde H, Lunder N, Refsum H, (2006) Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 28: 744-749.
34. Wood MD, Scott C, Clarke K, Westaway J, Davies CH, et al. (2006) Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol 546: 88-94.
35. Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, et al. (1990) The relationship between global and local changes in PET scans [see comments]. J Cereb Blood Flow Metab 10: 458-466.
36. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, et al. (1996) Comparison of methods for analysis of clinical [11C]raclopride studies. Journal of Cerebral Blood Flow & Metabolism 16: 42-52.
37. Lammertsma AA, Hume SP, (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-158.
38. Patlak CS, Blasberg RG, (1985) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 5: 584-590.
39. Gjedde A (1988) Exchange diffusion of large neutral amino acids between blood and brain. In: Rakic L, Begley DJ, Davson H, Zlokovic BV, editors. Peptide and amino acid transport mechanisms in the cerebral nervous system. New York: Stockton Press. pp. 209-217.
40. Hartvig P, Agren H, Reibring L, Tedroff J, Bjurling P, et al. (1991) Brain kinetics of L-[β-11C]dopa in humans studied by positron emission tomography. J Neural Transm Gen Sect 86: 25-41.
41. Brown RM, Crane AM, Goldman PS, (1979) Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates. Brain Res 168: 133-150.
42. Lloyd KG, Hornykiewicz O, (1972) Occurrence and distribution of aromatic L-amino acid (L-DOPA) decarboxylase in the human brain. J Neurochem 19: 1549-1559.
43. Ito H, Shidahara M, Takano H, Takahashi H, Nozaki S, et al. (2007) Mapping of central dopamine synthesis in man using positron emission tomography with L-[β-11C]DOPA. Ann Nucl Med 21: 355-360.